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Abstract
BACKGROUND: The minigastrin analogue — CP04: DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 has been developed for 
CCK2R targeting. This analogue can be radiolabelled with 111In or 68Ga for imaging, or with 90Y and 177Lu for therapy. However, 
affinity of the chelator-peptide conjugates to the cell membrane receptors may vary depending on the metal incorporated into 
the complex. So far, there are no such studies for the ligands of gastrin/cholecystokinin receptor CCK2R. It is supposed that 
the reason for the differentiation of receptor affinity to the respective receptors is in the changes of structure of chelating system 
and their influence on the bioactive conformations of the metal conjugated peptides. Herein, we report on the radiolabelling 
of CP04 with 90Y, 177Lu and 68Ga and synthesis of cold CP04 complexes with respective stable metals for further structural and 
physico-chemical and biological studies.
MATERIALS AND METHODS: From 200 to 600 MBq of 90Y, 177Lu or 68Ga were used for radiolabelling of 20 µg of CP04 dis-
solved in ascorbic acid solution (50 mg/mL, pH 4.5). Non-radioactive complexes with Lu and Ga were synthesized in milligram 
amounts starting from 0.5 mg up to 5 mg of CP04 dissolved in ascorbic acid solution (50 mg/mL, pH 4.5) when using 2-molar 
excess of the metal ions. Complex formation needed 5 min in microwave oven or 12 min in thermo-block at 95°C. RP-HPLC 
isocratic method (Kinetex 150/4.6 mm; 25% AcN/0.1% TFA, 1 mL/min) with UV/Vis and radiometric detection was developed 
for investigation of the radiolabelled and “cold” complexes. For LC-MS investigations, HPLC method was modified replacing 
TFA by formic acid.
RESULTS AND DISCUSSION: Yields of CP04 radiolabelling were greater than 90% for all three radionuclides. The HPLC 
method enabled identification of these radio-complexes based on comparison to their non-radioactive equivalents. In all cases, 
chromatograms revealed peaks that could be attributed to the metal-CP04 complexes and to impurities (including methionine 
oxidation). LC-MS analysis of Ga and Lu complexes revealed conformity of the observed molecular ions to the predicted 
formulas (m/z 2116 and 2220 Da for Ga and Lu, respectively). Different chromatographic behaviour observed for Ga-CP04 
complex comparing to Lu- and Y- labelled peptide (relative retention to CP04: 1.08, 0.86 and 0.85, respectively) suggest dif-
ferent coordination of the metal ions. Therefore, further studies are planned using the non-radioactive complexes in order to 
assess their structural conformations.
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Background
The cholecystokinin receptor type 2 (CCK-2R) is overexpressed 
in MTC with very high density and incidence over 90%, as revealed 
by autoradiographic studies [1]. According to these findings suit-
able tracers for targeting this particular receptor were developed. 
From the late 90s last century, a variety of CCK-2/gastrin related 
peptides (members of the gastrin- and cholecystokinin families, or 
possessing characteristics of both), were radiolabelled and studied 
in vitro (in terms of proper peptide sequence synthesis, stability 
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of the compound in serum, receptor affinity and binding) and in 
preclinical animal models (in terms of biodistribution, excretion path-
ways and uptake ratios in tumour to various organs) [2–8]. Some 
of these radiopeptides were tested in small clinical pilot-studies in 
humans. Receptor targeting was seen to some extent in physio-
logically CCK-2/gastrin receptor expressing tissues and most im-
portantly, in the tumour tissue with the high tumour to background 
ratios. In the attempt to enable therapy with CCK-2/gastrin recep-
tor-binding radiolabelled analogues further research was stimulated 
and coordinated within the European COST BM0607 project. Novel 
analogues were synthetized and comparatively evaluated both in 
vitro as well as in vivo regarding stability, receptor binding and 
tumour targeting [3–8]. As a result of  these comparisons one de-
rivative, namely DOTA-DGlu-DGlu-DGlu-DGlu-DGlu-DGlu-Ala-Tyr-G
lu-Trp-Met-Asp-Phe-NH2 (CP04, Fig. 1) showed the most promising 
characteristics in terms of high stability and receptor affinity, high 
and persistent tumour uptake and low kidney retention. Therefore, 
111In-CP04 was selected for further clinical evaluation [9].
The gastrin and CCK-2 receptors are potential targets for radio-
nuclide therapies, because ligands such as CP04 can be radiola-
belled with 111In or 68Ga for imaging, or with 90Y and 177Lu for therapy. 
Recently, the influence of 111In-radiolabelled DOTA-minigastrin 
analogues stereochemistry on their in vitro and in vivo behaviour 
was evaluated [10]. Despite the very small difference in these 
analogues due to the stereochemistry of the spacers the biologi-
cal distribution differed significantly in terms of accumulation in the 
tumour and kidney retention. In order to fully understand the mecha-
nisms responsible for these differences, the authors emphasize the 
need for further studies on the influence of radiotracer’s secondary 
structure on its pharmacokinetics.
Affinity of the chelator-peptide conjugates to the cell membrane 
receptors may also vary depending on the metal incorporated into 
the complex. This phenomenon has been observed both in vitro and 
in vivo for the radiocomplexes of DOTA conjugated somatostatin 
and bombesin analogues [11–13]. It is supposed that the reason 
for the differentiation of receptor affinity to the respective recep-
tors is in the changes of structure of chelating system and their 
influence on the bioactive conformations of the metal conjugated 
peptides [14]. However, stability of the metal complexes may be 
an additional factor that influences the affinity to the receptors [15]. 
So far, there are no such studies for the ligands of gastrin/cholecys-
tokinin receptor CCK2R.
In line with the above need, the aim of our project was to 
investigate the influence of selected metals on the structure and 
properties of DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 
(CP04), a gastrin/CCK analogue. Herein, we report on the radiola-
belling of CP04 with 90Y, 177Lu and 68Ga, the synthesis of cold CP04 
complexes with respective stable metals, and on their preliminary 
characterisation by HPLC and LC-MS methods.
Materials and methods
Optimization of CP04 radiolabelling with 90Y  
by microwave synthesis 
The microwave oven was used for investigation of the influence 
of temperature and reaction time on the 90Y-labelling yield of CP04 
and on its oxidation. For the radiolabelling 600 MBq of 90Y (ItraPol, 
NCBJ OR POLATOM) was added to 20 µg of CP04 (Pichem, Austria) 
dissolved in 0.2 mL of ascorbic acid buffer (50 mg/mL, pH 4.5) 
and incubated in microwave oven (Initiator, Biotage) at 95°C and 
98°C from 5 to 25 min.
Radiolabelling of CP04 with 90Y, 177Lu and 111In
For radiolabelling 200-600 MBq of 90Y (ItraPol, NCBJ OR PO-
LATOM), 177Lu (LutaPol, NCBJ OR POLATOM) or 111In (Mallinckrodt) 
was added to 20 µg of CP04 (Pichem, Austria) dissolved in 0.2 mL 
of ascorbic acid buffer (50 mg/mL, pH 4.5) and incubated in the 
microwave oven (Initiator, Biotage) for 5 min or in thermo-block at 
95°C for 12 min.
Radiolabelling of CP04 with 68Ga
200 µL of 68Ga eluate (200 MBq) from 68Ge/68Ga generator 
(iThemba) was added to 20 µL of CP04 (1 mg/mL) and 70 µL of 2.5 
M CH3COONa, followed by 12 min incubation at 95°C. It was then 
diluted with 710 µL of ascorbic acid (50 mg/mL, pH 4.5).
Synthesis of the cold complexes of CP04  
with Ga, Lu and Y for LC-MS study
The non-radioactive complexes of CP04 with Lu, Y, In and Ga 
were synthesized in milligram amounts starting from 0.5 mg up to 
5 mg of peptide dissolved in ascorbic acid buffer (50 mg/mL, pH 
4.5) using 2-fold molar excess of the metal ion. Incubation was car-
ried out for 5 min in microwave oven or 15 min in thermo-block at 
95oC followed by purification on SPE C18 columns.
Figure 1. Structure of CP04 peptide
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Determination of partition coefficient (log P)
For the determination of octanol/water partition coefficients, the 
aliquots (50 µL) of radiolabelled CP04 complexes were diluted with 
PBS (pH 7.4) to 500 µL and added to 500 µL of octanol in a testing 
tube, each in six replicates. The mixture was vigorously vortexed 
over a period of 15 min at room temperature (RT). After centrifuga-
tion, the radioactivity of 50 µL aliquots of both layers was measured 
in an automatic gamma counter (1470 Wizard, Wallac) and the log 
P value was calculated.
Analytical method
RP-HPLC isocratic method (Kinetex 150/4.6 mm; 25% AcN/0.1% 
TFA, 1 mL/min; oven temp. 40°C) with UV/Vis and radiometric 
detection was devised for investigation of the radiolabelled and 
“cold” CP04 complexes.
LC-MS study
LC-MS investigations were performed using the UFLC Shi-
madzu (Kioto, KYT, Japan) system coupled with ABI 4000 QTRAP 
linear ion trap quadrupole LC/MS/MS mass spectrometer (AB 
Sciex, Foster City, CA).
Analysis parameters: Kinetex 5u C18 100A, 4.6 × 150 mm co-
lumn; 25%AcN/0.1% TFA (in some experiments TFA was replaced 
with formic acid); flow rate 1 mL/min; t = 30°C; ionization electro-
spray (ESI)/positive; ion spray voltage, 5.5 kV; desolvatation tem-
perature, 700°C; curtain gas, 10 psi. Optimal spectra were obtained 
from Enhanced MS (EMS) scans at low (40V) declustering potential.
Results and discussion
A macrocyclic chelator DOTA (1,4,7,10-tetraazocyclodode-
cane-1,4,7,10-tetraacetic acid) is one of the most often used 
chelators for coupling to peptides for PRRT (peptide receptor 
radionuclide therapy) [16, 17], however the reaction kinetics differ 
for each radiometal. Hence, depending on whether the 90Y, 111In 
or 177Lu are planned to be used, the optimization of radiolabelling 
conditions is required. In addition, the elevated temperature and 
incubation time may influence the rate of undesired radiochemical 
species formation. Contrary to traditional heating devices used 
for radiolabelling, the microwave heating assures that desired 
temperatures are reached rapidly in a fully controlled radiolabelling 
process. Thus, microwave heating shortens incubation time, which 
might be critical in case of oxidation-sensitive peptides.
Methionine present in the amino acid sequence of CP04 peptide 
might be oxidised during labelling at elevated temperature, resulting 
in reduced receptor affinity. Therefore control of oxidation was criti-
cal for the quality of potential CP04 based radiopharmaceutical. 
The microwave oven used in our experiments (Initiator, Biotage) 
allowed precise control of heating temperature with an infrared sen-
sor. Already after 5 min incubation in the microwave oven at 95oC 
the radiolabelling yield greater than 99% (calculated in reference 
to unbound 90Y radioactivity) was obtained. The isocratic HPLC 
method with Kinetex 5u C18 column provided good resolution and 
allowed the quantitation of observed peaks. The peaks revealed in 
the radiochromatograms could be attributed to radiolabelled CP04 
and to the impurities such as a free radiometal and oxidized form of 
CP04 due to the methionine oxidation. Radiochemical purity of 90Y-
CP04 depended on the time of incubation and was decreasing with 
increase of incubation time (Table 1). At 5, 15 and 25 min incubation 
the radiochemical purity was 94.4%, 92% and 89.6%, respectively, 
while the contribution of radioactive oxidized forms of CP04 (Rt 
ca. 3.5–3.8 min) increased (from 1.2% to 5.8% after 5 and 25 min, 
respectively). Therefore, for further studies we kept the incubation 
time as short as possible to obtain 90Y-DOTA-gastrin of high RCP 
and to avoid of the methionine residue oxidation.
Cold complexes of CP04 with Y, Lu and Ga were synthesized 
in sufficient quantities to allow their stability and LC-MS studies. 
Radiometal complexes of CP04 with 90Y, 177Lu and 68Ga were ob-
tained with yields greater than 90% and their identity was confirmed 
by HPLC in comparison to their non-radioactive equivalents. In all 
cases, HPLC chromatograms revealed peaks that could be attri-
buted to the metal-CP04 complexes and to the impurities (including 
complexes with the oxidized peptide, Rt ca. 2.3–2.9 min). Different 
chromatographic behaviour observed for Ga- complex compa-
ring to Lu- and Y-CP04 (relative retention to CP04: 1.08, 0.86 and 
0.85, respectively) suggests different coordination of the metal 
ions (Fig. 2). The partition coefficient Log P values of −2.92 ± 0.005 
were determined for 90Y-CP04 as well as for 177Lu-CP04 while it 
was −2.68 ± 0.03 for 68Ga-CP04, what suggests a slightly higher 
lipophilicity of the gallium complex.
LC-MS analysis of Ga and Lu complexes revealed conformity 
of the observed molecular ions to the predicted formulas (m/z 2116 
Table 1. Radiolabelling yields and radiochemical purity of 90Y-CP04 complexes synthesized in microwave oven
Parameters: temp., time Yield [%] Radiochemical Purity of 90Y-CP04 [%] Oxidized CP04 [%]
95°C, 5 min 99.4 94.4 1.2
95°C, 15 min 99.7 92.0 3.8
95°C, 25 min 99.6 89.6 5.8
98°C, 5 min 99.7 93.3 2.5
Figure 2. Radiochromatograms of 177Lu-CP04, 90Y-CP04 and 68Ga- 
-CP04 (Kinetex 150/4.6 mm; 25%AcN/0.1% TFA, 1 mL/min)
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and 2220 Da for Ga and Lu, respectively; Fig. 3, Table 2). In the 
Ga complex only 2 carboxylic groups of DOTA are involved in the 
coordination, whereas 3 carboxylic groups are needed for Lu, Y 
and In. This results in different geometry of complexes with CP04. 
Our observations are in accordance with those by Viola-Villegas et 
al. [18], who proposed different structures for Ga- and Lu/Y-DOTA 
complexes.
Conclusions
Our study showed that the DOTA conjugated minigastrin 
analogue, CP04, can be easily and efficiently radiolabelled both 
with positron emitting radionuclide 68Ga, as well as with beta 
minus emitting radionuclides such as yttrium-90 or lutetium-177. 
However, different coordination of radiometals may lead to dif-
ferent physico-chemical and biological properties of these radio-
complexes. LC-MS study revealed that in case of yttrium and 
lutetium complexes, 3 carboxylic groups of DOTA are involved in 
the radiometal coordination, whereas in case of gallium only 2. 
This structural difference causes differential hydrophilicity of the Ga- 
and Y/Lu- complexes what has been observed in chromatographic 
and partition coefficient studies.
Further in vitro and in vivo studies are in progress to indicate 
whether the type of coordination of radiometal by DOTA bifunc-
tional chelator significantly influences the biological properties of 
radiolabelled CP04 and its interaction with CCK-2 receptors in vivo.
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Figure 3. The mass spectra of: A. CP04 peptide; B. Ga-CP04 complex; C. Lu-CP04 complex
A
B
C
Table 2. Characteristic of metal complexes with CP04
Compound Relative retention (r) 
(mob. phase with TFA)
Molecular mass [g/mol] Number of carboxylic groups  
of DOTA coordinating metal ion
CP04 1 2049 –
Ga-CP04 1.08 2116 2
Lu-CP04 0.86 2220 3
Y-CP04 0.85 2135 3
In-CP04 0.86 2161 3
[M/2 + 2H]2+ = 1025.5
[M/2 + 2H]2+ = 1058.9
[M/2 + 2H]2+ = 1111.4
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